New Drug Application Submitted to FDA for Fixed-Dose Atazanavir/Cobicistat Combo for HIV-1 Patients

A new drug application has been submitted to the FDA for a fixed-dose combination of atazanavir sulfate, a protease inhibitor marketed as Reyataz , and cobicistat , an investigational pharmacokinetic enhancer, or boosting agent, that can increase the level of certain human immunodeficiency virus-1 medications in the blood and make them more ... (more)

http://ift.tt/1eGOLBM